insulin glargine + technosphere insulin

This drug is a combination therapy consisting of insulin glargine, a long-acting basal insulin analog, and technosphere insulin, an ultra-rapid-acting inhaled human insulin formulation. Insulin glargine provides steady basal glycemic control over approximately 24 hours by mimicking the body’s natural background secretion of insulin[5]. Technosphere insulin is delivered via oral inhalation as a dry powder; it uses fumaryl diketopiperazine (FDKP) microparticles to rapidly deliver regular human insulin into systemic circulation through the lungs, achieving peak serum concentrations in about 12–15 minutes[1][2]. This combination is used for intensive glycemic management in diabetes mellitus—typically type 1 diabetes—where basal-bolus regimens are required. The approach aims to optimize both fasting and postprandial glucose control while reducing injection burden and potentially improving adherence[4][6].

Brand names

Afrezza + Lantus

Other names

TI + insulin glarginetechnosphere inhaled insulin + insulin glargineinhaled technosphere insulin + insulin glarginetechnosphere insulin + glargine